Sort
48,018 grants matching “immunotherapy”
A Yeast-based Immunotherapy against Clostridioides difficile infection
$554,355Zhiyong Yang · Fzata, Inc. · R44 · FY2021 · AI
Magnetically directed single cell transcriptome analysis in HIV latency
$554,322David Martin Murdoch · Duke University · R01 · FY2019 · AI
Magnetically directed single cell transcriptome analysis in HIV latency
$554,322David Martin Murdoch · Duke University · R01 · FY2018 · GM
âPharmacologic targeting of NR4A1 and NR4A2 to activate glioblastoma treatment responseâ
$554,314Robert C Rostomily · Methodist Hospital Research Institute · R01 · FY2025 · NS
Magnetically directed single cell transcriptome analysis in HIV latency
$554,169David Martin Murdoch · Duke University · R01 · FY2020 · AI
Advancing RAS pathway targeted therapy in NF1-MPNST: effects of SHP2 and CDK4/6 inhibitors on the tumor and the tumor immune microenvironment
$554,153Christine Anne Pratilas · Johns Hopkins University · R01 · FY2023 · CA
Training Program in Immunology
$554,153Gwendalyn J Randolph · Washington University · T32 · FY2023 · AI
Defining the β-catenin/CBP-catenin/CBP axis in head and neck cancer
$554,143Maria A Kukuruzinska · Boston University Medical Campus · R01 · FY2025 · DE
Treating colon cancer by regulating intestinal immunity through microbial metabolism
$554,126Nicholas Arpaia · Columbia University Health Sciences · R01 · FY2022 · CA
Treating colon cancer by regulating intestinal immunity through microbial metabolism
$554,126Nicholas Arpaia · Columbia University Health Sciences · R01 · FY2023 · CA
A Novel Anti-HER2/neu IgE for Breast Cancer Therapy
$554,058Manuel L Penichet · University Of California Los Angeles · R01 · FY2017 · CA
Project 2
$554,018Paolo Provenzano · University Of Minnesota · P01 · FY2025 · CA
Project 2
$554,018Paolo Provenzano · University Of Minnesota · P01 · FY2021 · CA
Improving anti-tumor T cell immunity by targeting LDH-A functions beyond the Warburg effect
$553,873Vassiliki A Boussiotis · Beth Israel Deaconess Medical Center · R01 · FY2019 · CA
Sulindac sensitizes colorectal cancer to anti-PD-L1 therapy
$553,817Yaguang Xi · Lsu Health Sciences Center · R01 · FY2022 · CA
Delineating Functional Immunity via Image-Guided PET
$553,790Nerissa Therese Viola · Wayne State University · R37 · FY2024 · CA
Role of IRF2 in cancer immune evasion and immunotherapy
$553,729Kenneth L Rock · Univ Of Massachusetts Med Sch Worcester · R01 · FY2024 · CA
Project 1: Blood Immunomethylomic Markers of Outcome in Glioblastoma Patients
$553,721John K. Wiencke · University Of California, San Francisco · P50 · FY2018 · CA
THERAPEUTIC MANUFACTURING
$553,636Leland H Hartwell · Fred Hutchinson Cancer Research Center · P30 · FY2009 · CA
Engineered Vaccines for Neoantigen Targeted Cancer Immunotherapy
$553,633John Tanner Wilson · Vanderbilt University · R01 · FY2023 · CA
TCR signaling and cell cycle regulation in tumor-specific CD8 T cell dysfunction
$553,614Mary Philip · Vanderbilt University Medical Center · R37 · FY2025 · CA
Overcoming hypoxic resistance to anti-cancer therapy
$553,580Nicholas C Denko · Ohio State University · R01 · FY2024 · CA
Therapy Resistance Mechanisms for Cancer
$553,548Javed Khan · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
A deubiquitination module controls Treg adaptation to tumor microenvironment
$553,526Deyu Fang · Northwestern University At Chicago · R01 · FY2022 · CA
MECHANISMS OF MURINE TUMOR ERADICATION BY IMMUNOTHERAPY
$553,481University Of Washington · R37 · FY2004 · CA